Corvus Pharmaceuticals, Inc. Common Stock Offering

Davis Polk advised the joint book-running managers in connection with a $69 million SEC-registered common stock offering by Corvus Pharmaceuticals, Inc. The common stock is listed on the Nasdaq Global Market under the symbol “CRVS.”

Corvus is a clinical-stage biopharmaceutical company focused on the development of novel immuno-oncology therapies.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Emily Roberts and Ali DeGolia. The tax team included partner Rachel D. Kleinberg and associate M. Brett Cameron. The intellectual property and technology team included counsel Michelle Ontiveros Gross and associate Jason J. Bang. Associate Colleen Blanco provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.